40 reports

Type ## Diabetes Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • APAC
  • World
  • Demand

Global Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Forecast

Diabetes Type ## Market and Forecast Analysis to 2025 CONTENTS ## FORECAST: TYPE ## DIABETES (Published on ## June 2017) ## OVERVIEW ## EXECUTIVE SUMMARY ## MARKET OVERVIEW AND TRENDS ## MARKET DEFINITION AND METHODOLOGY ## LATEST ANALYST OPINION ## APIDRA (INSULIN GLULISINE) ##

  • Type 1 Diabetes
  • European Union
  • Japan
  • United States
  • Demand
  • TOP-LINE PREVALENCE FOR TYPE 1 DIABETES MELLITUS
  • Prevalence of Type 1 Diabetes Mellitus, females (000s)

Prevalence of Type ## Diabetes Mellitus, males (##s) Table ##.

  • Chronic Disease
  • Diabetes
  • Pathology
  • Type 1 Diabetes

Type ## Diabetes (T##D) Market Size, Forecast And Trend Analysis, 2014 - 2024 Chapter ##.

  • Insulin
  • Therapy
  • Type 1 Diabetes
  • United States
  • Forecast

Europe Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 1 Diabetes
  • Europe
  • France
  • Germany
  • Forecast

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Market Shares
  • Market Size
  • TYPE 1 DIABETES DRUGS MARKET IN EMEA 2015-2020 ($ BILLIONS)
  • SEGMENTATION OF TYPE 1 DIABETES DRUGS MARKET BY DRUG CLASS

Phase II Type ## diabetes Type ## Diabetes ANTI-IL ## T##D (NN##) TEPLIZUMAB (MGA##) PROCHYMAL MacroGenics Company Stage of development Indication OI##GT (NN1953) Novo Nordisk ULTRA-RAPID INSULIN Eli Lilly PF-## BHV## HIP-##B NN1956 Pfizer BHV Pharma CureDm Novo Nordisk P

  • Diabetes
  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Japan
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • United States
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • United Kingdom
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Italy
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Germany
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • France
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Spain
  • Market Size
  • Type 1 Diabetes
  • TYPE 1 DIABETES WITH HYPOGLYCEMIA

THE COMPANY CLAIMS THAT DIABECELL IS EXPECTED TO BE ONE OF THE NOVEL THERAPEUTIC OPTIONS FOR REFRACTORY TYPE ## DIABETES. ##. ##. ##. ##.

  • Hospital
  • Type 1 Diabetes
  • United States
  • Erytech Pharma SA
  • Neurotech Pharmaceuticals, Inc.
  • North America Insulin Pumps Market, By Value
  • L: EUROPE REGIONAL MARKERS: HISTORIC AND FORECAST

Insulin Pumps Outlook Type I Diabetes: Type I diabetes is an autoimmune disease that destroys the insulin producing beta cells in the pancreas of the human body.

  • Insulin Delivery
  • Type 1 Diabetes
  • World
  • Market Size
  • Animas Corporation

Drug analysis: Farxiga

8770 10000 7800

Drug analysis: Farxiga PRODUCT PROFILES Farxiga : Diabetes type ## Farxiga : Diabetes type ## LIST OF FIGURES Figure ##: Farxiga for type ## diabetes – SWOT analysis Figure ##: Datamonitor Healthcare drug assessment of Farxiga Figure ##: Datamonitor Healthcare drug assessment scorecard

  • Diabetes
  • Type 1 Diabetes
  • European Union
  • Japan
  • United States

Insulin Glargine in Patients with Type ## Diabetes ## Jun ##, 2018: Xeris Pharmaceuticals Announces Positive Phase ## Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen ## Jun ##, 2018: Adding Liraglutide to Insulin Regimen for People with Type ## Diabetes Improved Gly

  • Chronic Disease
  • Clinical Trial
  • Therapy
  • Type 1 Diabetes
  • World
  • TYPE 1 DIABETES (JUVENILE DIABETES)
  • VACCINE FOR TYPE 1 DIABETES - DRUG PROFILE

NET LLC (INACTIVE) BIOTHERAPEUTICS INC BIRCHBIOMED INC BTB PHARMA AB CALADRIUS BIOSCIENCES INC CANCER PREVENTION PHARMACEUTICALS INC CARLINA TECHNOLOGIES SAS COMPUGEN LTD CYTEIR THERAPEUTICS INC DANCE BIOPHARM INC PR ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## P III ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company

The report focuses on drugs and therapies being evaluated for Type ## Diabetes (Juvenile Diabetes) treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Chronic Disease
  • Clinical Trial
  • Pathology
  • Type 1 Diabetes

2019 Type ## Diabetes Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets ##.

  • Chronic Disease
  • Clinical Trial
  • Drug Development
  • Type 1 Diabetes
  • APAC

Type ## Diabetes Pipeline Highlights – 2017 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • Product Initiative
  • 03/29/2018: EMA to Review Sotagliflozin as Potential Treatment for type 1 diabetes
  • Mar 26, 2018: Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes

" There are more than ## million adults with type ## diabetes in the United States alone, and the majority of these are not at their A##C goal of ## percent.

  • Pharmaceutical
  • Therapy
  • Type 1 Diabetes
  • United States
  • Lexicon Pharmaceuticals, Inc.
  • 05/22/2017: JDRF AND VIACYTE ANNOUNCE SUPPORT FOR DEVELOPMENT OF PEC-DIRECT CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES

Beyond Type ## seeks to make a better life for people living with type ## diabetes.

  • Healthcare
  • Therapy
  • Type 1 Diabetes
  • United States
  • ViaCyte, Inc.
  • 01/05/2017: ADOCIA LAUNCHES NEW MULTI-HORMONAL COMBINATION PROJECT FOR TREATMENT OF TYPE 1 DIABETES

In type ## diabetes, ultimately, neither insulin nor amylin is secreted and GLP-## secretion is deficient.

  • Insulin
  • Type 1 Diabetes
  • United States
  • Company
  • Adocia
  • BIOARTIFICIAL PANCREAS - TYPE 1 DIABETES - PRODUCT STATUS
  • BIOARTIFICIAL PANCREAS - TYPE 1 DIABETES - PRODUCT DESCRIPTION

Ly with Type ## Diabetes Over Five Days Under Free-Living Conditions Location: Oral Presentation - W## Monday June ## Time: ##:## - ##:## PM Location: Poster Hall Time: ##:## - ##:## PM Location: Poster Hall Sunday June ## Time: ##:## - ##:## PM Location: Poster Hall Time: ##:

  • Clinical Trial
  • Diabetes Monitoring
  • Insulin Delivery
  • Type 1 Diabetes
  • Medtronic, Inc.
  • Jul 18, 2018: Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus
  • Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma

Supported by funding from JDRF, the leading global organization funding type ## diabetes (T##D) research, OHSU is conducting a Phase ## singlecenter, randomized, three-way, controlled, crossover clinical study to test the efficacy of a new closed-loop algorithm for managing blood gluc

  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • Company
  • XERIS Pharmaceuticals, Inc.
  • Jul 18, 2018: Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus
  • Juvenile Diabetes Research Partners with Xeris Pharma and LATITUDE Pharma

Supported by funding from JDRF, the leading global organization funding type ## diabetes (T##D) research, OHSU is conducting a Phase ## singlecenter, randomized, three-way, controlled, crossover clinical study to test the efficacy of a new closed-loop algorithm for managing blood gluc

  • Pharmaceutical
  • Type 1 Diabetes
  • United States
  • Company
  • XERIS Pharmaceuticals, Inc.